Format

Send to

Choose Destination
Curr Opin Genet Dev. 2008 Feb;18(1):62-7. doi: 10.1016/j.gde.2008.01.018. Epub 2008 Mar 12.

Utilization of genomic signatures to direct use of primary chemotherapy.

Author information

1
Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27708, United States.

Abstract

The success of treatment of cancer patients depends on matching the most effective therapeutic regimen with the characteristics of the individual patient, balancing benefit against risk of adverse events. The primary challenge in achieving this goal is the heterogeneity of the disease, recognizing that breast, lung, colon and other cancers are not single diseases but rather an array of disorders with distinct molecular mechanisms. Genomic analyses, and in particular gene expression profiling, has been shown to have the capacity to dissect this heterogeneity and afford opportunities to match therapies with the characteristics of the individual patient's tumor. Here we review the success in developing gene expression signatures that have the capability of predicting response to various commonly used and newly developing cancer therapeutics. We further discuss the challenges and the opportunities in utilizing these tools in present-day clinical practice.

PMID:
18339540
DOI:
10.1016/j.gde.2008.01.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center